Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
https://www.zacks.com/stock/news/2208792/mirati-mrtx-gets-eu-nod-for-krazati-in-kras-mutated-nsclc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208792
Jan 11, 2024 - Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.
0
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
https://www.zacks.com/stock/news/2216537/analysts-estimate-bristol-myers-squibb-bmy-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2216537
Jan 26, 2024 - Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up
https://www.zacks.com/stock/news/2218877/2seventy-bio-tsvt-divests-r-d-assets-to-regeneron-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2218877
Jan 31, 2024 - 2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.
0
BLS Jobs Up Big: 353K, 3.7% Unemployment
https://www.zacks.com/stock/news/2220369/bls-jobs-up-big-353k-3-7-unemployment?cid=CS-ZC-FT-ahead_of_wall_street-2220369
Feb 02, 2024 - 353K new jobs created for January are nearly double the 180K or so analysts were looking for.
0
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More
https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529
Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
0
JAZZ Boosts Oncology Pipeline With KRAS Inhibitor Program
https://www.zacks.com/stock/news/2223497/jazz-boosts-oncology-pipeline-with-kras-inhibitor-program?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2223497
Feb 08, 2024 - JAZZ inks a deal to acquire global rights to Redx Pharma's KRAS inhibitor program to strengthen its early-stage oncology pipeline.
0
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline
https://www.zacks.com/stock/news/2225414/gilead-gild-to-buy-cbay-for-4-3b-add-pbc-drug-to-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2225414
Feb 13, 2024 - Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
0
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2237621/bristol-myers-squibb-bmy-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2237621
Mar 07, 2024 - In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.28, indicating a -0.19% shift from the previous trading day.
0
Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion
https://www.zacks.com/stock/news/2242244/bristol-myers-bmy-abecma-gets-odac-votes-for-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242244
Mar 18, 2024 - Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
0
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B
https://www.zacks.com/stock/news/2243580/astrazeneca-azn-to-buy-fusion-pharmaceuticals-for-2-4b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243580
Mar 20, 2024 - AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.
0